search
Back to results

TDCs to Treat Drug-resistant Epilepsy

Primary Purpose

Other Forms of Epilepsy, Treatment Resistant

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Cathodal tDCS
Sponsored by
Spanish Foundation for Neurometrics Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Other Forms of Epilepsy, Treatment Resistant focused on measuring Drug-resistant epilepsy, tDCS

Eligibility Criteria

18 Months - 120 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age 18-90 montths Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose. At least 2-3 seizure per month documented with EEG, not only clinically. In good health except epilepsy. Patients or his(her) familys could understand this method and sign the informed consent 7)Patients with good compliance and could complete postoperative follow-up. Exclusion Criteria: Results of MRI remind epilepsy caused by intracranial space-occupying lesions. Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma,mental disease,pepticulcer,diabetes Type 1,bad health etc, and other surgical contraindication sleep-related breathing disorders

Sites / Locations

  • Spanish Foundation for Neurometrics Development

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Refractory Epilepsy Group

Placebo Patients

Arm Description

50 patients with at least they have 3 crisis per week They Receive Cathodal tDCS We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31

50 patients with at least they have 3 crisis per week that receive SHAM They Not Receive Cathodal tDCS. We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31

Outcomes

Primary Outcome Measures

Decrease in number of crisis per day
Improve epilepsy and EEG (NO statistically and clinically significant spikes or slow waves were observed in EEG)., and changes in scale: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
Body mass index
kg / m^2

Secondary Outcome Measures

Quality live improve
less drugs consum and number of crisis per week, or moderate changes in EEG or brainwaves
Kessler Foundation Neglect Assessment Process
During each assessment session, occupational therapists measured patients' functions with the KF-NAP, Functional Independence Measure (FIM™) and Barthel Index (BI)

Full Information

First Posted
September 14, 2017
Last Updated
April 10, 2023
Sponsor
Spanish Foundation for Neurometrics Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05825274
Brief Title
TDCs to Treat Drug-resistant Epilepsy
Official Title
Transcranial Direct Current Estimulation for the Treatment of Drug-resistant Epilepsy in Children
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
October 1, 2017 (Actual)
Study Completion Date
December 28, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Spanish Foundation for Neurometrics Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. It encompass a wide spectrum of conditions, intensities and seizure types; therefor, several drugs have proven to treat different types of seizures. However, around 22.5 % of patients are unable to attain control regardless of the drug used or even a combination of several of them. TDCs offers a non-invasive approach with a focal effect for those patients. The focus of this study is to define the role for tDCS in the treatment of drug-resistant epilepsy on children.
Detailed Description
Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. There are between 16 and 51 new cases per 100 000 people every year. A community-based study conducted in France concluded that up to 22.5 % of patients could be classified as presenting drug-resistant epilepsy. This group presents significant hazards such as an increased risk of death, injuries, psychosocial disfunction and a reduced quality of life. The International League against Epilepsy defines drug-resistant epilepsy as follows: A failure of adequate trials of two (or more) tolerated, appropriately chosen, appropriately used antiepileptic drugs (whether administered as monotherapies or in a combination) to achieve freedom from seizures. This significant amount of patients are the drive to develop different approaches in order to offer alternatives for control. In this regard, non-invasive brain stimulation protocols lead the way, since the pathophysiological substrate of epilepsy is an enhanced cortical excitability, leading to paroxysmal depolarisation shifts, an enhanced probability of high-frequent and hypersyncronous activity of small neuronal networks and the abnormal spreading of this pathological activity along cortico-cortical and cortico-subcortical neuronal conections. Transcranial direct current stimulation (tDCS) consists of short-lasting electric stimulus delivered to specific brain regions. When delivered repidetly, it generates long-lasting cortical excitability alterations and thus, has the potential to treat epilepsy targeting to the specific brain region where the cortical excitability is alterated. The aim of this study is to define the role for tDCS on the treatment of drug resistant epilepsy on children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Other Forms of Epilepsy, Treatment Resistant
Keywords
Drug-resistant epilepsy, tDCS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment
Masking
None (Open Label)
Masking Description
we use in half of patient cathodal tDCS or Brain noninvasive stimulation
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Refractory Epilepsy Group
Arm Type
Experimental
Arm Description
50 patients with at least they have 3 crisis per week They Receive Cathodal tDCS We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
Arm Title
Placebo Patients
Arm Type
Placebo Comparator
Arm Description
50 patients with at least they have 3 crisis per week that receive SHAM They Not Receive Cathodal tDCS. We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
Intervention Type
Device
Intervention Name(s)
Cathodal tDCS
Other Intervention Name(s)
Brain Noninvasive Electrical Stimulation, tDCS
Intervention Description
We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
Primary Outcome Measure Information:
Title
Decrease in number of crisis per day
Description
Improve epilepsy and EEG (NO statistically and clinically significant spikes or slow waves were observed in EEG)., and changes in scale: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
Time Frame
4 months
Title
Body mass index
Description
kg / m^2
Time Frame
4 Months
Secondary Outcome Measure Information:
Title
Quality live improve
Description
less drugs consum and number of crisis per week, or moderate changes in EEG or brainwaves
Time Frame
4 months
Title
Kessler Foundation Neglect Assessment Process
Description
During each assessment session, occupational therapists measured patients' functions with the KF-NAP, Functional Independence Measure (FIM™) and Barthel Index (BI)
Time Frame
4 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Months
Maximum Age & Unit of Time
120 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18-90 montths Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose. At least 2-3 seizure per month documented with EEG, not only clinically. In good health except epilepsy. Patients or his(her) familys could understand this method and sign the informed consent 7)Patients with good compliance and could complete postoperative follow-up. Exclusion Criteria: Results of MRI remind epilepsy caused by intracranial space-occupying lesions. Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma,mental disease,pepticulcer,diabetes Type 1,bad health etc, and other surgical contraindication sleep-related breathing disorders
Facility Information:
Facility Name
Spanish Foundation for Neurometrics Development
City
Elche
State/Province
Alicante
ZIP/Postal Code
03201
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
neuroterapias.es is the database where our foundation recorda all the clinical data of our assays
IPD Sharing Time Frame
4 Months
IPD Sharing Access Criteria
login and password previous registration in neuroterapias.es
IPD Sharing URL
http://www.neuroterapias.es/
Citations:
PubMed Identifier
21885255
Citation
Varga ET, Terney D, Atkins MD, Nikanorova M, Jeppesen DS, Uldall P, Hjalgrim H, Beniczky S. Transcranial direct current stimulation in refractory continuous spikes and waves during slow sleep: a controlled study. Epilepsy Res. 2011 Nov;97(1-2):142-5. doi: 10.1016/j.eplepsyres.2011.07.016. Epub 2011 Aug 31.
Results Reference
background

Learn more about this trial

TDCs to Treat Drug-resistant Epilepsy

We'll reach out to this number within 24 hrs